Second death may doom multiple sclerosis drug
Cambridge life-sciences company Biogen Idec Inc. last night was plunged deeper into crisis by news that yet another patient taking its troubled Tysabri drug had died of the rare condition PML.
That's the third patient discovered to have developed PML, a neurological disorder, while taking Tysabri and the second to die from the disease. ``This is a worst-case scenario,'' Sanford C. Bernstein analyst Geoffrey Porges said last night. ``There is now a 1-in-10 chance that this drug ever comes back.''